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Endoglin (CD105) is upregulated in endothelial cells of tissues undergoing neovascularisation. A greater number of CD105-positive
vessels predicts poor survival in breast cancer. We examine whether CD105 expression predicts response to neoadjuvant
chemotherapy. Fifty-seven women (median age 50 years, range 29–70) received neoadjuvant chemotherapy for operable breast
cancer. Immunohistochemical staining using monoclonal antibodies to CD105 and CD34 was performed on pretreatment biopsies
and post-treatment surgical specimens. Individual microvessels were counted in 10 random fields at  200 magnification. Median
counts were correlated with clinical and pathological response using the Mann–Whitney U-test. Forty-five out of fifty-seven patients
(79%) responded clinically, 22 (39%) responded pathologically. On pretreatment biopsies, clinical responders had significantly lower
median CD105-positive vessel counts than nonresponders (median counts 5 and 9.3/high-power field (hpf), median difference¼4.0/
hpf, 95% CI 0.5–8.0/hpf, P¼0.02). For pathological responders and nonresponders, median counts were 4.8 and 5.5/hpf (median
difference –0.5/hpf, 95% CI¼ 2.5–2.0/hpf, P¼0.77). CD34 expression (total microvessel density) did not correlate with response.
Pretreatment CD105 expression predicts for clinical response to chemotherapy, with a lower initial count being favourable. Patients
with high baseline new vessel counts or increased counts after conventional therapy may benefit from additional antiangiogenic
therapy.
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The formation of new blood vessels, angiogenesis, is a requirement
for the growth of tumours and for the development of metastases
(Folkman, 1990). Angiogenic activity is heterogeneous within a
tumour type, and surrogate markers such as microvessel density
are commonly used to quantify angiogenesis. Microvessel density
can be scored by immunohistochemistry using antibodies against
factor VIII-associated antigen, PECAM-1/CD 31 or CD 34. This
technique was developed by Weidner et al (1991), initially using
antibodies against factor VIII-related antigen that stain mainly
mature vessels. The more recent use of antibodies against CD31
(platelet endothelial cell adhesion molecule) and CD34 also stain
immature vessels and are thus referred to as panendothelial
markers. The assessment of microvessel density has been related
to the presence of metastases (Weidner et al, 1991) and overall
survival in breast cancer (Bosari et al, 1992). A meta-analysis of 43
independent studies by Uzzan et al (2004) revealed that a high
microvessel density significantly predicts for a poor survival
(relative risk¼1.54, 95% CI¼1.29–1.84).
Endoglin (CD105) is a cell-surface glycoprotein that binds with
high affinity to transforming growth factors (TGF) b1 and b3
(Cheifetz et al, 1992) which are involved in regulation of cell
differentiation and proliferation in most cell types. The association
of CD105 with angiogenesis initially came from Wang et al (1993)
who found that monoclonal antibodies to CD105 reacted strongly
with the endothelium in various tumour tissues but only weakly in
normal tissues. CD105 is overexpressed on endothelial cells of
tissues undergoing neovascularisation and is strongly expressed in
breast cancer (Bodey et al, 1998). Blood vessels in several normal
human tissues used as controls contained significantly lower levels
of CD105 in accordance with the slow turnover of normal
endothelial cells in comparison with tumour cells. Unlike CD31
and CD34, which stain both mature and immature vessels, CD105
appears to be much more specific for new, immature vessels.
There is evidence that conventional neoadjuvant chemotherapy
can reduce the microvessel density in primary breast cancer
(Makris et al, 1999; Bottini et al, 2002). Staining of surgical
histopathological samples with CD34 monoclonal antibody in
patients who had received neoadjuvant chemotherapy was
compared with staining of samples from patients who had
undergone primary surgery to be later followed by adjuvant
chemotherapy. The median scores of microvessel staining were
significantly lower in the neoadjuvant group (Makris et al, 1999).
This raises the possibility that chemotherapy directly affects
angiogenesis, although the reduction in microvessel density may
be secondary to tumour regression caused by the neoadjuvant
treatment. The purpose of this study was to investigate whether
CD105 staining is influenced by neoadjuvant treatment of breast
cancer with chemotherapy and whether pretreatment CD105
staining on biopsy specimens is predictive of response to
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schemotherapy. A comparison of new vessel counts (CD105
expression) and total vessel counts (CD34 expression) was also
planned.
MATERIALS AND METHODS
Fifty-seven female breast cancer patients were recruited prospec-
tively and consecutively from the Mount Vernon cancer network.
The study was open to all women about to undergo neoadjuvant
chemotherapy for primary operable breast cancer for tumours
larger than 2cm in diameter at presentation (T2-4, N0-2, M0). As
part of routine management, all patients underwent a trucut or
mammotome biopsy to confirm the diagnosis before commencing
treatment. Participants were consented to allow additional
immunohistochemical examination of the tissue excised at biopsy
and at definitive surgery. Twenty-two of the patients were
recruited as part of a concurrent study of the role of dynamic
magnetic resonance imaging in predicting response to neoadjuvant
chemotherapy. Patients were scheduled to receive six cycles of
5-fluorouracil, epirubicin and cyclophosphamide chemotherapy
on a 21-day cycle. Doses used were 5-fluorouracil 500mgm
 2,
epirubicin 75mgm
 2, and cyclophosphamide 500mgm
 2.
Immunohistochemical staining for CD105 was performed
retrospectively on pretreatment biopsy specimens and post-
treatment surgical specimens. The formalin-fixed paraffin-em-
bedded tumour specimens were dewaxed and rehydrated through
graded alcohols. Following rinsing in Tris-buffered saline Tween,
endogenous peroxidase was blocked using Dako peroxidase block
and a protein block was applied. CD105 antibody (DakoCytoma-
tion, Cat No. M3527, Glostrup, Denmark) diluted to 1/1000 in
Dako S2022 antibody diluent was applied and the specimen
incubated for 1h. This is a longer incubation time than
recommended by the Dako kit, but we have previously found that
a shorter time results in weak or negative staining. The following
antibodies and reagents were each applied for 15-min incubations
with Tris buffer washings in between: anti-mouse IgG-IgG-HRP,
amplification reagent and anti-fluorescein-HRP. Following DAB
substrate application and a further 5-min incubation, the speci-
mens were rinsed in water, counterstained with haematoxylin,
dehydrated through alcohol and mounted. Isotopic IgG controls
were performed with all runs; positive controls were breast and
tonsil tumours.
Microscope fields were observed at a magnification of  200
(field of view¼493.1 368.5mm
 1) and the number of vessels
staining positive for CD105 on a single field were counted. The
next field was chosen randomly but systematically by moving the
view on by five field widths. This process was repeated so that
vessel counts were obtained for 10 random fields. For small biopsy
specimens of less than 10 fields in size, the whole specimen was
counted. The median value was calculated for each specimen and
expressed as count per high-power field (hpf). One observer, with
no knowledge of patient details or outcomes, performed the main
analysis. Although the observer was clearly aware of which were
the biopsies and which were the surgical specimens, he had no
knowledge of the responder status of the patient. A second
observer independently scored 10 of the specimens (chosen at
random) using the same technique to assess interobserver
variability. Furthermore, additional sections from 10 of the
specimens were stained on a different date and counted separately
to assess the reliability of the staining methods.
Clinical response was determined by physical examination in
outpatient clinics. Patients were routinely examined before each
cycle of chemotherapy and were judged to be clinical responders if
at the end of the course of chemotherapy, the tumour had shrunk
in longest diameter by 50% or more from the initial prechemo-
therapy measurement. All patients also underwent mammography
and/or ultrasound examinations before commencing therapy
and on completion of chemotherapy, but for the purpose of this
study clinical response was determined by examination alone.
A surgical specimen was declared to show a pathological
response if there was evidence of an apparent reduction in tumour
cell-to-stroma ratio or if the following chemotherapy-induced
changes were observed: (1) enlarged cells, (2) finely vacuolated,
voluminous cytoplasm, (3) an enlarged vesicular nucleus with a
prominent single eosinophilic nucleolus, (4) occasionally an
enlarged hyperchromatic dense nucleus with an irregular outline,
(5) compact hyalinized fibrous tissue at the site of good tumour
response. Surgical specimens that demonstrated none of these
features were declared to be non-responders pathologically.
Median CD105 counts were compared for pretreatment vs post-
treatment specimens. Counts were then grouped into clinical
responders and nonresponders and pathological responders and
nonresponders. These groups were then analysed using the Mann–
Whitney U-test for nonparametric data (StatsDirectt, Cheshire,
UK) and two-sided P-values obtained. Absolute change of paired
pretreatment biopsy and post-treatment surgery specimens was
evaluated using Wilcoxon’s signed-rank test for the group as a
whole and by clinical and pathological response category. In
addition, the percentage change in CD105-positive vessel counts
from biopsy to surgery was calculated and response groups were
again compared using the Mann–Whitney U-test.
Specimens were also stained using anti-CD34 antibody (Novo-
castra Labs Ltd, Newcastle, UK, NCL-L-ENDt) using a similar
technique to that described for the CD105 antibody and total vessel
counts were obtained using the same counting methods. Median
baseline CD34 counts were analysed by clinical and pathological
response categories and differences between the groups assessed
using the Mann–Whitney U-test. For each specimen, an estimate
of the proportion of ‘activated vessels’ (CD105 counts/CD34
counts) was expressed as a percentage, and these percentage
values were again compared by response category.
RESULTS
Table 1 shows the patient and tumour characteristics for the 57
women in the study. Forty-five of the 57 patients (79%) were
judged to have had a clinical response, whereas 22 patients (39%)
had a pathological response according to the aforementioned
criteria. Four patients did not proceed to surgery – three had a
complete clinical and radiological response and were offered the
option of no surgery, whereas the fourth patient declined surgery
despite having no discernable clinical response. These patients
were still included in the analysis of clinical response and biopsy
vessel staining, but could not be analysed for pathological
response.
On the prechemotherapy biopsy specimens, the number of fields
counted ranged from four to 10 (median¼10). The median
CD105-positive vessel counts per field ranged from 0 to 18.5
(median¼4). For the postchemotherapy surgical specimens, 10
fields were counted in all patients, with a CD105-positive vessel
count range of 0–38 (median¼3). Interobserver variability was
assessed on 10 specimens counted by both observers. Figure 1A
shows the comparison of vessel counts by each observer, giving a
correlation coefficient of 0.948 (r
2¼0.899). Similarly, correlation
coefficients were determined for vessel counts from stains
performed on alternative sections from 10 specimens (0.949,
r
2¼0.882) and this comparison is shown in Figure 1B.
Comparison of biopsy specimens from clinical responders
(n¼45) and nonresponders (n¼12) revealed median CD105
counts of 5 and 9.3/hpf, respectively (Mann–Whitney U-test for
probability of difference in distributions P¼0.02, see Table 2).
On pretreatment biopsies, there was no significant difference
in CD105 staining between pathological responders and non-
responders (median counts of 4.8 and 5.5/hpf respectively,
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sP¼0.77). Figure 2 shows the distribution of CD105 counts from
biopsy specimens, grouped for both clinical and pathological
response.
For analysis of the postchemotherapy surgical specimens, eight
patients were excluded. Four of these did not undergo surgery
for reasons outlined above and a further four had a complete
pathological response and hence had no tumour to stain. Fifteen of
the remaining patients were classified as pathological responders
and 34 as nonresponders. The median CD105-positive vessel
counts on the surgical specimens are shown by response category
in Table 2.
Comparison of individual paired results from biopsy and
surgical specimens using Wilcoxon’s signed-rank test revealed a
median difference of 0.25/hpf (95% CI –1.75 to 2.25/hpf, P¼0.81)
for the whole group, excluding the four nonsurgery and four
complete pathological response patients. In clinical responders, the
median difference between biopsy and surgical vessel counts was
 0.25/hpf (95% CI –2.25 to 1.75/hpf, P¼0.81) and in clinical
nonresponders it was 2.05/hpf (95% CI –8.75 to 8.0/hpf, P¼0.52).
In pathological responders, the median difference was 2.13/hpf
(95% CI 0.0 to 4.5/hpf, P¼0.057) and in nonresponders it was –
0.75/hpf (95% CI –3.5 to 2.0/hpf, P¼0.51).
An analysis of the percentage change in CD105-positive vessels
from pretreatment biopsy to post-treatment surgical specimens
reveals a mean decrease of 11% in pathological responders (95% CI
 69.3 to 47.1%). Pathological nonresponders had a mean increase
in CD105 vessels of 129.1% from biopsy to surgical specimens
(95% CI 8.2–250.1%). This difference did not achieve significance
on the Mann–Whitney U-test (P¼0.11). The four pathological
Table 1 Patient and tumour characteristics
Number of patients 57
Age (years)
Median 50
Range 29–70
Initial tumour stage
T1 0
T2 37
T3 15
T4 5
N0 30
N1 23
N2 2
N3 2
Endocrine status
ER +ve/PR +ve 29
ER  ve/PR  ve 16
ER +ve/PR  ve 5
ER  ve/PR +ve 1
ER +ve/PR unknown 4
Unknown 2
Grade
11
22 3
32 7
Unknown 6
A
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Figure 1 (A) Comparison of CD105-positive vessel counts per hpf for
observer 1 and observer 2 on 10 randomly chosen specimens. (B)
Comparison of CD105-positive vessel counts per hpf for different sections
of the same specimen for 10 randomly chosen cases.
Table 2 Median CD105 and CD34-positive vessel counts per hpf for biopsy and surgical specimens grouped by clinical and pathological response
categories
Response
CD105 counts/hpf CD34 counts/hpf
assessment Responders Nonresponders Median difference
a Responders Nonresponders Median difference
a
Biopsy specimens Clinical 5.0 9.3  4.0 ( 8.0 to  0.5) 10.5 17.0  5.0 ( 9.5 to1.0)
P¼0.02 P¼0.09
Pathological 4.8 5.5  0.5 ( 2.5 to 2.0) 3.0 5.8  2.5 ( 5.5 to 0.5)
P¼0.77 P¼0.12
Surgical specimens Clinical 5.0 4.0  0.5 ( 6.5 to 3.0) 12.5 12.0  0.5 ( 8.0 to 5.0)
P¼0.40 P¼0.93
Pathological 3.0 5.8  2.5 ( 5.5 to 0.5) 13.5 11.3 1.5 ( 4.0 to 6.0)
P¼0.12 P¼0.60
aMedian differences between responders and nonresponders are shown with 95% CI in parentheses and Mann–Whitney U-test P-values for differences in distributions.
Endoglin as a response predictor in breast cancer
MJ Beresford et al
1685
British Journal of Cancer (2006) 95(12), 1683–1688 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
scomplete responders necessarily had a 100% decrease in CD105-
positive vessels (owing to no tumour remaining for assessment)
and were excluded from this analysis. The percentage change in
CD105-positive staining is represented in Figure 3.
The results for CD34 staining are shown grouped by response
category alongside those for CD105 in Table 2. A ratio of new to
total vessel counts (CD105-positive counts/CD34-positive counts)
was obtained for each patient and expressed as a percentage.
Table 3 shows the median ‘activated vessel’ percentages for biopsy
and surgical specimens grouped by clinical and pathological
response assessments. It can be seen that this ratio does not differ
between responders and nonresponders. Paired comparisons of
the ‘activated vessel’ ratio between biopsy and surgery specimens
using Wilcoxon’s signed-rank test revealed a median difference of
4.1% (95% CI –11.5 to 20.4, P¼0.61).
DISCUSSION
Endoglin (CD105) is a 180-kDa integral membrane glycoprotein
that binds with high affinity to TGF b1 and b3 (Cheifetz et al,
1992). Transforming growth factor b is a member of a group of
growth factors involved in inhibition and regulation of cell
differentiation and proliferation in most cell types via interaction
with transmembrane serine and threonine kinase receptor com-
plexes (Massague, 1990). CD105 binds TGFb and modulates
signalling by antagonising some of its effects. In CD105-deficient
cells, the inhibitory effects of TGFb on proliferation and migration
were found to be enhanced (Li et al, 2000a,b), thus implying that
abundant expression of CD105 might shield cells from the
inhibitory effects of TGFb.
In breast cancer tissue, CD105 expression is inversely correlated
with both overall and disease-free survival. Kumar et al (1999)
assessed microvessel density in 106 patients using monoclonal
antibodies to CD105 and the panendothelial marker CD34. CD105
expression correlated significantly with overall (P¼0.0029) and
disease-free (P¼0.0362) survival, whereas CD34 counts showed no
such relationship (Kumar et al, 1999). Dales et al (2004) examined
the prognostic significance of CD105 and CD31 immunocyto-
chemical expression in 905 breast cancers. A greater number of
CD105-positive microvessels correlated significantly with a poorer
survival (P¼0.001) both on uni- and multivariate analysis. This
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Figure 2 Box and whisker plots showing the distribution of median
CD105-positive vessel counts per hpf from pretreatment biopsy specimens
grouped by (A) clinical response and (B) pathological response. Mann–
Whitney U-test for differences in distributions (A) P¼0.02, (B) P¼0.77.
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Figure 3 Box and whisker plot of the percentage change from
prechemotherapy biopsy to post-chemotherapy surgical CD105-positive
vessel counts, grouped by pathological response. Mann–Whitney U-test
for differences in distributions P¼0.11.
Table 3 Percentage of activated vessels (CD105/CD34 ratio) on biopsy
and surgical specimens grouped by clinical and pathological response
assessments
% Activated vessels (CD105/CD34 ratio)
Response
assessment
Responder
(%)
Nonresponder
(%)
Median
difference
a
Biopsy Clinical 40.7 47.7  3% ( 25.2 to 25.0)
P¼0.65
Pathological 32.0 46.4 0% ( 21.0 to 18.5)
P¼0.94
Surgery Clinical 34.8 32.2 0% ( 22.2 to 24.5)
P¼0.93
Pathological 26.9 38.9  8.9% ( 28.6 to 10.7)
P¼0.36
aMedian differences between responders and non-responders are shown with 95%
CI in parentheses and Mann–Whitney U-test P-values for differences in distributions.
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scorrelation was also seen in a subgroup of node-negative patients
(P¼0.035). CD31 expression correlated with poor survival, but not
in the node-negative subgroup and not on multivariate analysis
(Dales et al, 2004). It should be noted, however, that there is cross-
reactivity of CD31 antibodies with fibroblasts and plasma cells
leading to a degree of over-staining, which is not seen when using
the more specific CD34 (Leek, 2001). CD105 might turn out to be a
superior prognostic indicator to established panendothelial
markers. Given that CD105 has been known as an endothelial
marker for some time now, it is surprising that it has not been
more extensively investigated.
The aim of our study was to take this as a step further to see
whether the poor prognosis suggested by a high CD105 count
could be related to a poor response to chemotherapy treatment.
Neoadjuvant chemotherapy allows useful assessment of tumour
response to treatment, both clinically and pathologically, and we
could therefore observe changes in CD105 staining in relation to
response. We show that clinical responders are more likely to have
lower baseline CD105-positive vessel counts than clinical non-
responders, and thus that high CD105 counts might be a predictor
of a poor response to chemotherapy. However, assessment of
pathological response did not appear to be related to pretreatment
CD105 counts.
In patients with a good pathological response, the post-
treatment median CD105-positive count was lower than those
with no pathological response, but this did not achieve signifi-
cance. It should be noted that the best (complete) pathological
responders were excluded from this part of the analysis by
necessity as there was no remaining tumour to stain. The median
counts reported for ‘pathological responders’ might therefore be
falsely high, thus resulting in a loss of significance.
Analysis of the percentage changes in positive staining between
pre- and post-treatment specimens reveals an interesting trend.
There is a tendency for pathological responders to show a modest
decrease in CD105 staining, whereas nonresponders show an
increase. The wide confidence limits prevent this from achieving
significance, but again the complete responders are excluded.
We found that although there was a trend for lower pretreat-
ment CD34 expression in clinical or pathological responders,
unlike with CD105 these values did not achieve statistical
significance. This gives further evidence that CD105 is a superior
predictive marker to CD34/31 total microvessel density. Our
analysis of the ratio of ‘activated’ or new vessels to total vessels
(CD105 counts/CD34 counts) did not show any significant
correlations with response, nor did the ratio change significantly
after chemotherapy treatment. It should be noted that from the 18
statistical analyses performed in this study, the only one to achieve
statistical significance was in relation to clinical response
assessment and baseline CD105 counts. The possibility of chance
findings must be considered, and it should also be noted that some
of the other tests showed strong trends that failed to achieve
statistical significance, but may be worth examining with a larger
sample group.
Assessment of endoglin may have other applications in the
management of breast cancer. For example, elevated levels
of soluble CD105 have been found in the plasma of breast
cancer patients when compared with normal controls, and
particularly high levels have been linked with metastatic disease
(Li et al, 2000a,b). Furstenberger et al (2006) recently looked at
changes in serum levels of soluble angiogenesis-related factors in
breast cancer patients receiving anthracycline or taxane-based
neoadjuvant chemotherapy. Although there were no differences
in baseline levels of soluble CD105 between patients and
controls, they found that patients demonstrated significant
decrease in circulating levels of soluble CD105 after two cycles of
chemotherapy (Po0.01).
With the emergence of new data on the efficacy of antiangio-
genic agents in breast cancer (Thorpe, 2004), it has become more
important to assess tumour vasculature and the relationship with
conventional cytotoxic agents. Our findings fit with recent
evidence to suggest that newly activated vessels may be structurally
and functionally abnormal. Jain (2005) showed that new vessels
are leaky, tortuous and have haphazard connections and irregular
basement membranes. These abnormalities lead to heterogeneity
in tumour blood flow and thus to interstitial hypertension, hypoxia
and metabolic disturbance. This in turn might result in poor drug
delivery to the tumour, thus explaining why patients with higher
baseline CD105 expression might have a worse response to
chemotherapy (and is consistent with the poor prognosis found
to be associated with high counts in other studies).
In summary, this study suggests that a lower baseline CD105-
positive vessel count is favourable for a good clinical response to
conventional chemotherapy. The trend towards increased CD105
expression after neoadjuvant chemotherapy in pathological non-
responders could be explained by the induction of angiogenesis
in resistant tumours. The introduction of antiangiogenic agents
such as bevacizumab in this setting should be investigated in
prospective studies.
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